INS and type 2 diabetes mellitus: Our real-world results confirm that these antidiabetic non-insulin drugs are safe for the treatment of T2DM in a standard-of-care regimen with a maximum tolerated doses, even when administered in association with the CV drugs used for the treatment of HBP, such as BB or CCB, and with ACEI or ARB, or for the treatment of dyslipidemia with statins, or when compared to metformin.